Biosimilars Market To Surpass USD 91 81 Bn By 2030 On Account Of Rising Healthcare Costs & Advancements In Biotechnology menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., has announced the acquisition of Viatris' Biosimilars assets for up to $3.335 billion (Rs 25K crore) in stock and cash.
She said the deal will enable BBL to attain a robust commercial engine in the developed markets of U.S. & Europe and will fast-track the company s journey of building a strong global brand. Biocon Biologics to Acquire Viatris Biosimilars Assets for Up to USD 3.335 Billion in Stock and Cash.